T h e tumour suppressor protein, PTEN (phosphatase and tensin homologue deleted on chromosome 10) is a member of the mixed function, serine/threonine/tyrosine phosphatase subfamily of protein phosphatases. Its physiological substrates, however, are primarily 3-phosphorylated inositol phospholipids, which are products of phosphoinositide 3-kinases. PTEN thus antagonizes PI 3-kinase-dependent signalling pathways, which explains to a large extent its tumour suppressor status. We have examined the kinetic behaviour, substrate specificity and regulation of PTEN both in oitro and in a variety of cellular models. Although PTEN can utilize both phosphatidylinositol 3,4,5-trisphosphate [PtdIns-(3,4,5)P,] and its water-soluble headgroup, inositol 1,3,4,5-tetrakisphosphate, as substrates, it displays classical features of interfacial catalysis, which greatly favour the lipid substrate (by as much as 1000-fold as judged by K,,,/K,,, values).
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Expression of PTEN in U87 cells (which lack endogenous PTEN) and measuring the levels of all known 3-phosphorylated lipids suggests that phosphatidylinositol 3,4-bisphosphate and PtdIns(3,4,5)P3 are both substrates, but that phosphatidylinositol 3-phosphate and phosphatidylinositol 3,s-bisphosphate are not. P T E N binds to several PDZ-domain-containing proteins via a consensus sequence at its extreme C-terminus. Disruption of targeting to PDZ-domain proteins selectively blocks some PTEN functions, but not others, suggesting the existence of spatially localized, functionally dedicated pools of signalling lipids. We have also shown recently that P T E N expression is controlled at the transcriptional level and is profoundly upregulated by peroxisome proliferator activated receptor y agonists, thereby providing possible implications for these drugs in diabetes, inflammation and cancer.
Introduction
T h e are several compelling lines of evidence for the claim that PTEN (phosphatase and tensin homologue deleted on chromosome 10) is a human tumour suppresser gene. It was first identified in 1997 as a locus that was mutated frequently in sporadic glioblastomas, prostate and breast cancers and that is located at chromosome 10q23 in a region that is deleted at very high frequency in PTEN mutations are associated with a wide range of tumours, most frequently endometrial tumours and glioblastomas. Germline mutations in PTEN result in the uncommon autosomal dominant hamartomatous syndromes, Cowden disease and Bannayan-Ruvalcaba-Rily syndrome. Cowden disease sufferers experience a greatly increased risk of breast and thyroid tumours. T h e critical importance of PTEN during development is indicated by the fact that PTEN knockout mice die during embryogenesis between days 6.5 and 9.5.
Mice that are heterozygous at the PTEN locus, however, develop normally, but are susceptible to a wide range of tumours later in life, similar to human Cowden disease patients. This evidence is summarized in several recent reviews [3-51.
T h e PTEN gene encodes a 403 amino acid protein (PTEN) that is a member of the protein tyrosine phosphatase (PTP) subfamily of protein phosphatases. Its primary physiological substrates, however, are 3-phosphorylated inositol phospholipids, which are products of phosphoinositide 3-kinases (PI 3-kinases). P T E N thus antagonizes PI 3-kinase-dependent signalling pathways, in large part explaining its tumoursuppresser status. T h e discovery that P T E N metabolizes 3-phosphoinositide lipid signals arose from the failure to identify convincing protein substrates, which culminated in the observation that the most promising peptide-based substrates contained multiple acidic residues. This led Tonks and co-workers to propose acidic phospholipids as possible substrates [6] , an idea that was first addressed by Maehama and Dixon [7] . They established that P T E N metabolized phosphoinositide substrates in eitro and in cell lines, while Myers et al. [S] subsequently linked the ability to metabolize lipids with tumour suppresser activity using a mutant (G129E) that lacked lipid phosphatase activity, but retained phosphotyrosine phosphatase activity, and which occurs in Cowden disease patients.
T h e connections between PTEN, its lipid substrates, the signalling pathways that they control and tumour suppression are now well established. Much less is known about P T E N as a suppresser of insulin action or in inflammatory responses involving neutrophils and macrophages, two areas of biology in which PI 3-kinasedependent signalling pathways have decisive roles [9-121. Moreover, there is very little information on the factors and mechanisms that control the level of P T E N activity in cells. In this paper, we explore the kinetic behaviour of PTEN that contributes to its unexpected substrate specificity and identify two mechanisms of regulation involving spatial distribution of the enzyme [13, 14] and enhanced transcription of the PTEN gene stimulated by peroxisome proliferator activated receptor (PPAR) y agonists [15] . T h e latter results suggest a role for PTEN in inflammation and diabetes as well as cancer.
PTEN is a member of the protein tyrosine phosphatase family that is well adapted to utilizing phosphoinositide substrates T h e crystal structure of P T E N was solved recently by Lee et al. [16] . As predicted from the primary sequence it contains an N-terminal phosphatase domain, but it also possesses several characteristics that are not shared by other PTP enzymes and that direct the phosphatase towards lipid substrates. For example, P T E N has a Ca2'-independent C2 domain that can bind phospholipid vesicles in oitro and appears not only to allow transient association with cellular membranes, but also to play a role in ensuring the productive orientation of the active site. This idea is supported by the extensive interface between the phosphatase domain and the catalytic domain that is highly conserved in P T E N orthologues from different species, and is also a frequent target of mutations A further structural adaptation of P T E N involves the active site itself. T h e substrate-binding pocket in P T E N is both deeper and broader than in other PTPs for which structures have been determined, allowing access to the bulky polyphosphorylated inositol phospholipid headgroup. T h e cleft is also highly basic, consistent with the preference for acidic substrates. T h e domain structure of P T E N is illustrated in Figure 1 .
Early studies established that P T E N selectively removes the 3-phosphate from the water-soluble inositol 1,3,4,S-tetrakisphosphate [Ins(l, 3, 4, 5)P4] . Figure 2 illustrates the range of inositol phospholipids currently known to be present in eukaryotic cells and indicates 3-phosphorylated species that are potential substrates of PTEN. Our initial studies focused on phosphatidylinositol3,4,5-trisphosphate [PtdIns(3, 4, 5 )P3], the principal product of type I PI 3-kinases and an established mitogenic second messenger and insulin signalling molecule [ 171. For the kinetic analyses, recombinant human P T E N was prepared as a glutathione-Stransferase fusion protein, that is cleaved from this tag by thrombin, and purified to homogeneity. Synthetic phosphoinositides were mixed with PtdIns(3,4,5)P3 that had been labelled with 33P at the 3-position (by the action of recombinant PI 3-kinase y on phosphatidylinositol4,S-diphosphate) and with carrier lipids [usually phosphatidylcholine (PtdCho)]. Lipid vesicles of defined size were prepared by extrusion as described elsewhere T h e initial analyses were performed at a fixed PtdIns(3,4,5)P3 mole fraction of lo",, in a background of PtdCho. T h e activity appeared to obey simple Michaelis-Menten kinetics yielding &,,/Km values that were approximately 1 000-fold greater than the originally reported value [7] derived using Ins( 1,3,4,5)P, as substrate. We also confirmed, under a range of conditions that, when presented in a vesicular form, PtdIns(3,4,5)P3 is a far superior substrate than its water-soluble headgroup. An important point is that PtdCho is a suitable background lipid for these experiments as it appears not directly to influence P T E N activity. By contrast, acidic phospholipids, such as PtdIns, phosphatidylserine and PTEN's product, phosphatidylinositol4,5-bisphosphate, are all effective inhibitors when present at high mole fractions in substrate-containing vesicles.
It was found that P T E N displays classical features of an interfacial enzyme, in large part explaining its great preference for vesicular presentation of its substrates. Interfacial enzymes bind to vesicles, micelles and/or cell membranes via non-catalytic sites, thereby allowing efficient V81.
Eukaryotic cells synthesize at least eight distinct phosphoinositide species -potential substrates of PTEN Phosphatidylinositol is synthesized by the combination of CMP-phosphatidate (CMP-PA) and rnyo-inosrtol (Ins) Almost 50 yearj of work on these compounds has identified the seven polyphosphoinosrtide species found in eukaryotic cells, which are shown in this figure These differ in terms of the number and distnbution of monoester phosphate groups around the six-membered inosrtol nng The arrows indicate known pathways of synthesis and degradation of these molecules Question marks indicate putative dephosphorylation reactions catalysed by PTEN which are addressed in the text Rdlns(3.4.5)P, is currently the only confirmed substrate of PTEN in living cells Further experiments along similar lines to those described above suggest a substrate order of preference of PtdIns(3,4,5)P3 > phosphatidylinositol 3,4-bisphosphate > phosphatidylinositol 3-phosphate. Moreover, experiments in which P T E N was overexpressed in a PTEN-null tumour cell line suggest that neither phosphatidylinositol 3-phosphate nor phosphatidylinositol 3,s-bisphosphate are cellular substrates of the expressed enzyme. This might be a reflection of their relative weakness as substrates in elityo, lack of accessibility of some potential substrates in intact cells. or both.
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Specific targeting of PTEN to PDZdomain protein scaffolds is impaired in a subset of human tumours
Although P T E N appears to be located mainly in the cytosol of most cells, the extreme C-terminus contains a consensus sequence that mediates interactions with a number of PDZ domains in several proteins. Of the proteins that bind P T E N in vitro and in overexpression studies, MAGI-2 is so far the only one for which an interaction with the endogenous protein has been demonstrated [20].
In our experiments we deleted the PDZ domain binding sequence (generating PTENstop), a strategy that has no measurable effect on the catalytic activity of PTEN, and analysed the effects on a range of cellular responses to PTEN expression. This manipulation had no detectable effect on the ability of P T E N to inhibit protein kinase B (PKB) activity, signalling components downstream of PKB or the PKB-independent activation of p70S6 kinase in PTEN-null U87 tumour cells. By contrast, this mutation severely blunted the inhibitory effect of PTEN expression on cell spreading in U87 cells and platelet-derived growth factorinduced membrane ruffling in Swiss 3T3 fibroblasts [13, 14] , suggesting that PDZ domain interactions are required for efficient inhibition of lamellipodia formation. This observation is particularly intriguing because the effects on lamellipodia required the lipid phosphatase activity of PTEN, but the expression of the PTENstop mutation made no detectable difference to the decrease in PtdIns(3,4,5)P3 levels that occurred in U87 cells, compared with the effect of wild-type PTEN. It seems, therefore, that PDZ domainmediated targeting of PTEN may play a role in the regulation of processes that are highly sensitive to small changes in the level of PtdIns(3,4,5)P3. This in turn suggests the possibility that a small localized pool of PtdIns(3,4,5)P3 is dedicated to regulating lamellipodia formation, but not the activation of PKB. We are currently seeking direct evidence for the involvement of dedicated pools of signalling lipids in the regulation of spatially localized cellular responses.
These data were also extended to include an analysis of tumours carrying mutations in the extreme C-terminus of PTEN, similar to the PTENstop mutation that we constructed. These experiments showed relatively low levels of PKB phosphorylation in a glioblastoma sample that carried such a C-terminal mutation compared with tumours carrying phosphatase-inactivating mutations of the enzyme [14] . This suggests that deregulation of PKB is not a universal feature of tumours that carry P T E N mutations. We postulate that the deficiency in these tumours reflects a failure to target P T E N to ensure efficient metabolism of a small PKB-independent pool of PtdIns(3,4,5)P,. Approx. 5 I),, of P T E N mutations in glioblastomas are on the C-terminal side of the C2 domain, but no such mutations occur in endometrial tumours. This might reflect the finding that P T E N mutation is an early event in endometrial tumour progression, but is associated with advanced malignant brain tumours [2 11. Cellular Ptdlns(3,4,5)P3 levels are controlled via upregulation of P E N gene transcription Although P T E N exists as a phosphoprotein in cells, there is no evidence for signalling pathways that regulate P T E N activity through acute changes in phosphorylation. Phosphorylation of a cluster of serine and threonine residues in the C-terminal tail of P T E N (possibly via casein kinase 2) appears to be important for stability of the enzyme presumably by inhibiting its degradation b y a proteosome-mediated pathway [22, 23] . Since these sites appear to be constitutively phosphorylated in cells it will be interesting to identify the protein phosphatase(s) that are responsible for dephosphorylation, since activation of such a pathway would be expected to dephosphorylate P T E N and perhaps target it for degradation. Such a mechanism could possibly account for the dramatic downregulation of P T E N expression that occurs in human keratinocytes treated with transforming growth factor p [24] . Upregulation is observed at the mRNA, protein and phosphoinositide 3-phosphatase activity levels by a mechanism that most likely involves the direct interaction of activated PPARy with one or more of the response elements noted above, although more work needs to be done to confirm this. These results suggest that upregulation of PTEN, with the concomitant downregulation of PI 3-kinase-dependent signalling pathways, might be one of the mechanisms through which PPARy agonists exert their anti-inflammatory and anti-cancer actions. There is an apparent paradox, however, in the efficacy of these compounds in the treatment of type I 1 diabetes, in which further blunting of PI 3-kinase signalling would be expected to be detrimental. However, it seems that overexpression of P T E N elicits a feedback mechanism that results in the upregulation of insulin receptor substrate 2 (IRS-2), one of a family of at least four adapter proteins through which insulin and some other stimuli activate PI 3-kinase [25] . Since transgenic IRS-2--mice exhibit many features of type I1 diabetes [26] , it is likely that the upregulation of IRS-2 seen with enhanced expression of P T E N will be beneficial in this disease.
Conclusions
We have established kinetic properties of P T E N that reveal its efficiency as an enzyme for metabolizing a lipid signal that is a very minor constituent of cell membranes. These studies also suggest, not only its remarkable adaptation as a lipid phosphatase, but also the very high degree of specificity towards PtdIns(3,4,5)P, as the physiologically relevant substrate. Although our studies do not address the question of whether P T E N has any protein phosphotyrosyl substrates, it seems unlikely that such substrates would show significant rates of dephosphorylation when compared with PtdIns(3,4,5)P,, given the large discrepancy between the latter and even a closely similar, soluble substrate such as Ins( 1,3,4,5)P,. Nevertheless it would be valuable to identify a mutation in P T E N that prevented tyrosine phosphatase activity without affecting the lipid phosphatase, since such a reagent would have the potential to reveal any P T E N functions that are independent of lipid phosphatase activity.
Unlike many second messenger-metabolizing enzymes, P T E N appears to be constitutively active, thereby making it well suited to maintaining low basal levels of PtdIns(3,4,5)P,, as well as being capable of blunting agonist-stimulated increases in this signal. This property is clearly an important feature of the tumour suppresser activity of PTEN. Moreover, it is not obvious that P T E N is regulated through acute covalent modifications or by translocation to signalling complexes. Changes in the level of expression of P T E N caused by stimuli such as transforming growth factor a or pharmacological agents such as PPARy agonists (or in heterozygotes with only one functional PTEN allele) appear to influence directly the set point of PI 3-kinase signalling activity. A key next step will be to identify the PTEN promoter in order to explore in more detail mechanisms of transcriptional regulation of enzyme expression.
